Optimistic Buy Rating for Opthea Limited: Sozinibercept’s Promising Phase 3 Potential and Market Positioning
Opthea Limited Sponsored ADR (OPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Opthea to Host Investor Days in New York and Australia
Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on ...
Opthea to Host Investor Days Highlighting Sozinibercept’s Potential in Wet AMD
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
manilatimes3d
HydroGraph Publishes 2025 CEO Letter to Shareholders
Hawkeye Bio selected HydroGraph's graphene for use in the company's biomedical sensor aimed at the early detection of lung ...
Opthea Announces Publication in Diabetic Macular Edema
Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...